JP2021512892A - 核酸分子送達のためのナノ粒子−ヒドロゲル複合材料 - Google Patents
核酸分子送達のためのナノ粒子−ヒドロゲル複合材料 Download PDFInfo
- Publication number
- JP2021512892A JP2021512892A JP2020542544A JP2020542544A JP2021512892A JP 2021512892 A JP2021512892 A JP 2021512892A JP 2020542544 A JP2020542544 A JP 2020542544A JP 2020542544 A JP2020542544 A JP 2020542544A JP 2021512892 A JP2021512892 A JP 2021512892A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- hsa
- peptide
- hairpin
- mirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 348
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 105
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 104
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 104
- 239000002131 composite material Substances 0.000 title description 178
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 469
- 239000002679 microRNA Substances 0.000 claims abstract description 306
- 239000002105 nanoparticle Substances 0.000 claims abstract description 216
- 125000002091 cationic group Chemical group 0.000 claims abstract description 122
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 96
- 150000001413 amino acids Chemical class 0.000 claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 claims description 196
- 108700011259 MicroRNAs Proteins 0.000 claims description 95
- 201000011510 cancer Diseases 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 65
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 50
- 230000004048 modification Effects 0.000 claims description 45
- 238000012986 modification Methods 0.000 claims description 45
- 230000007935 neutral effect Effects 0.000 claims description 36
- -1 hsa-miR-29c Proteins 0.000 claims description 35
- 239000007924 injection Substances 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 31
- 239000002246 antineoplastic agent Substances 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 21
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 229910052740 iodine Inorganic materials 0.000 claims description 18
- 229910052721 tungsten Inorganic materials 0.000 claims description 17
- 238000011084 recovery Methods 0.000 claims description 16
- 229910052720 vanadium Inorganic materials 0.000 claims description 16
- 229910052727 yttrium Inorganic materials 0.000 claims description 16
- 230000003278 mimic effect Effects 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 150000007942 carboxylates Chemical class 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 8
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 229960003104 ornithine Drugs 0.000 claims description 8
- 210000003281 pleural cavity Anatomy 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 108091069018 Homo sapiens miR-27b stem-loop Proteins 0.000 claims description 7
- 108091007424 MIR27B Proteins 0.000 claims description 7
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 7
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 6
- 108091070373 Homo sapiens miR-24-1 stem-loop Proteins 0.000 claims description 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 108091069094 Homo sapiens miR-134 stem-loop Proteins 0.000 claims description 4
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 claims description 4
- 108091069090 Homo sapiens miR-149 stem-loop Proteins 0.000 claims description 4
- 108091067995 Homo sapiens miR-192 stem-loop Proteins 0.000 claims description 4
- 108091069013 Homo sapiens miR-206 stem-loop Proteins 0.000 claims description 4
- 108091067578 Homo sapiens miR-215 stem-loop Proteins 0.000 claims description 4
- 108091067008 Homo sapiens miR-342 stem-loop Proteins 0.000 claims description 4
- 108091067267 Homo sapiens miR-370 stem-loop Proteins 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 210000005033 mesothelial cell Anatomy 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 108091070374 Homo sapiens miR-24-2 stem-loop Proteins 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 230000002381 testicular Effects 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 201000002513 peritoneal mesothelioma Diseases 0.000 claims description 2
- 208000016596 serous neoplasm Diseases 0.000 claims description 2
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 claims 2
- 108091069086 Homo sapiens miR-127 stem-loop Proteins 0.000 claims 2
- 108091044798 Homo sapiens miR-1287 stem-loop Proteins 0.000 claims 2
- 108091044790 Homo sapiens miR-1293 stem-loop Proteins 0.000 claims 2
- 108091044792 Homo sapiens miR-1294 stem-loop Proteins 0.000 claims 2
- 108091069024 Homo sapiens miR-132 stem-loop Proteins 0.000 claims 2
- 108091066990 Homo sapiens miR-133b stem-loop Proteins 0.000 claims 2
- 108091068987 Homo sapiens miR-135a-1 stem-loop Proteins 0.000 claims 2
- 108091069102 Homo sapiens miR-136 stem-loop Proteins 0.000 claims 2
- 108091067617 Homo sapiens miR-139 stem-loop Proteins 0.000 claims 2
- 108091068992 Homo sapiens miR-143 stem-loop Proteins 0.000 claims 2
- 108091051957 Homo sapiens miR-1538 stem-loop Proteins 0.000 claims 2
- 108091067627 Homo sapiens miR-182 stem-loop Proteins 0.000 claims 2
- 108091067605 Homo sapiens miR-183 stem-loop Proteins 0.000 claims 2
- 108091068960 Homo sapiens miR-195 stem-loop Proteins 0.000 claims 2
- 108091090626 Homo sapiens miR-2114 stem-loop Proteins 0.000 claims 2
- 108091067466 Homo sapiens miR-212 stem-loop Proteins 0.000 claims 2
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 claims 2
- 108091067573 Homo sapiens miR-222 stem-loop Proteins 0.000 claims 2
- 108091070492 Homo sapiens miR-23a stem-loop Proteins 0.000 claims 2
- 108091070400 Homo sapiens miR-27a stem-loop Proteins 0.000 claims 2
- 108091069021 Homo sapiens miR-30b stem-loop Proteins 0.000 claims 2
- 108091065163 Homo sapiens miR-30c-1 stem-loop Proteins 0.000 claims 2
- 108091072769 Homo sapiens miR-3145 stem-loop Proteins 0.000 claims 2
- 108091078081 Homo sapiens miR-320d-1 stem-loop Proteins 0.000 claims 2
- 108091056652 Homo sapiens miR-3610 stem-loop Proteins 0.000 claims 2
- 108091067535 Homo sapiens miR-375 stem-loop Proteins 0.000 claims 2
- 108091067563 Homo sapiens miR-376a-1 stem-loop Proteins 0.000 claims 2
- 108091092229 Homo sapiens miR-491 stem-loop Proteins 0.000 claims 2
- 108091092303 Homo sapiens miR-497 stem-loop Proteins 0.000 claims 2
- 108091064509 Homo sapiens miR-502 stem-loop Proteins 0.000 claims 2
- 108091064363 Homo sapiens miR-506 stem-loop Proteins 0.000 claims 2
- 108091064367 Homo sapiens miR-509-1 stem-loop Proteins 0.000 claims 2
- 108091061630 Homo sapiens miR-643 stem-loop Proteins 0.000 claims 2
- 108091061679 Homo sapiens miR-653 stem-loop Proteins 0.000 claims 2
- 108091060464 Homo sapiens miR-668 stem-loop Proteins 0.000 claims 2
- 108091055990 Homo sapiens miR-676 stem-loop Proteins 0.000 claims 2
- 108091087105 Homo sapiens miR-939 stem-loop Proteins 0.000 claims 2
- 108091070375 Homo sapiens miR-95 stem-loop Proteins 0.000 claims 2
- 108091070376 Homo sapiens miR-96 stem-loop Proteins 0.000 claims 2
- 108091007773 MIR100 Proteins 0.000 claims 2
- 108091008051 MIR27A Proteins 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108091070511 Homo sapiens let-7c stem-loop Proteins 0.000 claims 1
- 108091065981 Homo sapiens miR-155 stem-loop Proteins 0.000 claims 1
- 108091033120 Homo sapiens miR-196b stem-loop Proteins 0.000 claims 1
- 108091056533 Homo sapiens miR-3677 stem-loop Proteins 0.000 claims 1
- 108091055298 Homo sapiens miR-4472-1 stem-loop Proteins 0.000 claims 1
- 108091090385 Homo sapiens miR-4524b stem-loop Proteins 0.000 claims 1
- 108091023135 Homo sapiens miR-4675 stem-loop Proteins 0.000 claims 1
- 108091061594 Homo sapiens miR-590 stem-loop Proteins 0.000 claims 1
- 108091080241 Homo sapiens miR-8078 stem-loop Proteins 0.000 claims 1
- 108091027977 Mir-200 Proteins 0.000 claims 1
- 230000006510 metastatic growth Effects 0.000 claims 1
- 108091007432 miR-29b Proteins 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 abstract description 319
- 239000000499 gel Substances 0.000 abstract description 67
- 230000007704 transition Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 174
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 90
- 101710176384 Peptide 1 Proteins 0.000 description 90
- 238000011282 treatment Methods 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 101100129496 Arabidopsis thaliana CYP711A1 gene Proteins 0.000 description 32
- 101100083446 Danio rerio plekhh1 gene Proteins 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 238000001890 transfection Methods 0.000 description 25
- 238000001727 in vivo Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000004614 tumor growth Effects 0.000 description 19
- 206010027406 Mesothelioma Diseases 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 238000009826 distribution Methods 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 15
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 15
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 14
- 239000007995 HEPES buffer Substances 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 229920000669 heparin Polymers 0.000 description 14
- 229960002897 heparin Drugs 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 108091088730 miR-215 stem-loop Proteins 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 238000007920 subcutaneous administration Methods 0.000 description 14
- 229940124597 therapeutic agent Drugs 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000030279 gene silencing Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 238000012226 gene silencing method Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 10
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 229960002378 oftasceine Drugs 0.000 description 10
- 238000001338 self-assembly Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 238000002271 resection Methods 0.000 description 9
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 238000003917 TEM image Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000536 complexating effect Effects 0.000 description 8
- 210000001163 endosome Anatomy 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000008732 thymoma Diseases 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000001142 circular dichroism spectrum Methods 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002114 nanocomposite Substances 0.000 description 6
- 108091027963 non-coding RNA Proteins 0.000 description 6
- 102000042567 non-coding RNA Human genes 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 5
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 5
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 5
- 108010040476 FITC-annexin A5 Proteins 0.000 description 5
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 5
- 101000957259 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2A Proteins 0.000 description 5
- 102100026519 Lamin-B2 Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000942 confocal micrograph Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- SYNDQCRDGGCQRZ-VXLYETTFSA-N dynasore Chemical compound C1=C(O)C(O)=CC=C1\C=N\NC(=O)C1=CC2=CC=CC=C2C=C1O SYNDQCRDGGCQRZ-VXLYETTFSA-N 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- QDERNBXNXJCIQK-UHFFFAOYSA-N ethylisopropylamiloride Chemical compound CCN(C(C)C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl QDERNBXNXJCIQK-UHFFFAOYSA-N 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 229960005277 gemcitabine Drugs 0.000 description 5
- 108010052219 lamin B2 Proteins 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000005853 Clathrin Human genes 0.000 description 4
- 108010019874 Clathrin Proteins 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108091030146 MiRBase Proteins 0.000 description 4
- 102100038792 Mitotic spindle assembly checkpoint protein MAD2A Human genes 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 229930193282 clathrin Natural products 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 230000009881 electrostatic interaction Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 108091063796 miR-206 stem-loop Proteins 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 4
- 229960005079 pemetrexed Drugs 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000005660 hydrophilic surface Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 229960000988 nystatin Drugs 0.000 description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
- 210000004224 pleura Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000518 rheometry Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 101800002011 Amphipathic peptide Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000013378 biophysical characterization Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013000 chemical inhibitor Substances 0.000 description 2
- 231100000096 clonogenic assay Toxicity 0.000 description 2
- 238000009643 clonogenic assay Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000004651 endocytosis pathway Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 108091076060 miR-206-1 stem-loop Proteins 0.000 description 2
- 230000034778 micropinocytosis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- RPROHCOBMVQVIV-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCNC2 RPROHCOBMVQVIV-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000026557 AIDS-related primary central nervous system lymphoma Diseases 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 101710150620 Anionic peptide Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 101710102121 GTP-binding protein 1 Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010051676 Metastases to peritoneum Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- ZQTIUAFUBMGURF-UHFFFAOYSA-N [Cl-].I[NH+]1N=NN=C1 Chemical compound [Cl-].I[NH+]1N=NN=C1 ZQTIUAFUBMGURF-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000010415 colloidal nanoparticle Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000006565 epigenetic process Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 208000010918 peritoneal neoplasm Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 150000003679 valine derivatives Chemical group 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、全体が参照により組み込まれる2018年2月10日に出願された米国仮出願第62/628,961号の優先権を主張する。
本開示の分野
連邦政府により支援された研究および開発に関する陳述
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;nは、3〜5である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+7〜+10の正味の形式電荷を有する。
ペプチドのC末端は、カルボキシレートではなく、中性または正の電荷を有するペプチド改変を含む。一部の実施形態では、第1の両親媒性カチオン性ペプチドは、(1d)VKVKVKVKVDPPTKVKVKVKV−NH2(MAX1ペプチド)として記載されるアミノ酸配列を含むか、またはそれからなる。
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYから個別に選択され;Zはそれぞれ、任意のアミノ酸から個別に選択され;nは、3〜5である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+3〜+8の正味の形式電荷を有する。
一部の実施形態では、第2の両親媒性カチオン性ペプチドは、
VLTKVKTKVDPPTKVEVKVLV−NH2(HLT2ペプチド)
として記載されるアミノ酸配列を含むか、またはそれからなる。
添付の配列表に列挙されている核酸およびアミノ酸配列は、37C.F.R.1.822に規定されたように、ヌクレオチド塩基については標準の文字略語、およびアミノ酸については3文字コードを使用して示されている。各核酸配列の一方の鎖のみが示されているが、示されている鎖へのいかなる言及にも相補鎖が含まれると理解される。配列表は、参照により本明細書に組み込まれる2019年2月8日に作成された「Sequence.txt」という名称のファイル(約20kb)の形態でASCIIテキストファイルとして提出される。添付の配列表において:
詳細な説明
A.用語の概要
B.核酸送達のためのナノ粒子−ヒドロゲル複合材料
ナノ粒子
(1)(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+7〜+10(+7、+8、+9、または+10など)の正味の形式電荷を有する。
ペプチドのC末端は、カルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含む(例えば、C末端をアミド化してもよい)。ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれるが、水中に溶解した場合はβ−ヘアピンコンフォメーションにフォールディングされない。
(1a)(XZ)n XDPPX(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+7〜+10(+7、+8、+9、または+10など)の正味の形式電荷を有する。ペプチドのC末端は、カルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含む(例えば、C末端をアミド化してもよい)。ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれるが、水中に溶解した場合はβ−ヘアピンコンフォメーションにフォールディングされない。
(1b)(XZ)n XDPGX(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+7〜+10(+7、+8、+9、または+10など)の正味の形式電荷を有する。
ペプチドのC末端は、カルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含む(例えば、C末端をアミド化してもよい)。ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれるが、水中に溶解した場合はβ−ヘアピンコンフォメーションにフォールディングされない。
(1c)(XZ)n X NGX(ZX)n(配列番号1)
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+7〜+10(+7、+8、+9、または+10など)の正味の形式電荷を有する。
ペプチドのC末端は、カルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含む(例えば、C末端をアミド化してもよい)。ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれるが、水中に溶解した場合はβ−ヘアピンコンフォメーションにフォールディングされない。
(1d)VKVKVKVKVDPPTKVKVKVKV
(1e)VKVKVKVKVDPGTKVKVKVKV
(1f)VKVKVKVKV NGTKVKVKVKV(配列番号2)
として記載されるアミノ酸配列を含むか、またはそれからなる。
ナノ粒子中に含まれる核酸分子
表1. 開示されるナノ粒子−ヒドロゲル複合材料における使用のための例示的な成熟ヒトmiRNA
ペプチドヒドロゲル
(2)(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、任意のアミノ酸から個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+3〜+8(+3、+4、+5、+6、+7、または+8など)の正味の形式電荷を有する。
ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれる。
(2a)(XZ)n XDPPX(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、任意のアミノ酸から個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+3〜+8(+3、+4、+5、+6、+7、または+8など)の正味の形式電荷を有する。
ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれる。
(2b)(XZ)n XDPGX(ZX)n
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、任意のアミノ酸から個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+3〜+8(+3、+4、+5、+6、+7、または+8など)の正味の形式電荷を有する。
ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれる。
(2c)(XZ)n X NGX(ZX)n(配列番号94)
(式中、Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;Zはそれぞれ、任意のアミノ酸から個別に選択され;nは、3〜5(3、4または5など)である)として記載されるアミノ酸配列を含むか、またはそれからなり;そのペプチドは、中性pHで+3〜+8(+3、+4、+5、+6、+7、または+8など)の正味の形式電荷を有する。
ペプチドは、25℃で50mMのビストリスプロパン、pH7.4、150mMのNaCl中に2.0%w/vで溶解した場合、β−ヘアピンコンフォメーションに折り畳まれる。
(2d)VLTKVKTKVDPPTKVEVKVLV
(2e)VLTKVKTKVDPGTKVEVKVLV
(2f)VLTKVKTKV NGTKVEVKVLV(配列番号82)
として記載されるアミノ酸配列を含むか、またはそれからなる。
ナノ粒子−ヒドロゲル複合材料中のペプチドのさらなる説明
ナノ粒子−ヒドロゲル複合材料内に封入されるさらなる薬剤
C.がんの処置および防止
(実施例1)
ナノ複合材料ペプチドヒドロゲルネットワーク内でのマイクロRNA鋳型ペプチド集合
結論
方法
ナノ粒子の細胞内在化
(吸光度処理−吸光度低対照/吸光度高対照−吸光度低対照)×100
を使用して算出した。
(実施例2)
ペプチドコンフォメーションはmiRNAナノ粒子の機能性を変更する
Claims (41)
- ペプチドヒドロゲルであって、
前記ペプチドヒドロゲル内に封入されたナノ粒子を含み、前記ナノ粒子が、アンフォールドされ、β−ヘアピンコンフォメーションにない第1の両親媒性カチオン性β−ヘアピンペプチドと複合体化した核酸分子を含み、
前記ペプチドヒドロゲルが、β−ヘアピンコンフォメーションに折り畳まれた第2の両親媒性カチオン性β−ヘアピンペプチドの線維ネットワークから形成され;
前記ペプチドヒドロゲルが、剪断応力の印加の際に剪断減粘を受け、前記剪断応力の除去の際に流動学的回復を受け;
前記核酸分子が、アンチセンス核酸分子であり;
前記第1の両親媒性カチオン性β−ヘアピンペプチドの正味の静電荷が、中性pHで前記第2の両親媒性カチオン性β−ヘアピンペプチドの正味の静電荷と等しいか、またはそれより多くの正電荷を有し;
前記第1の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n−NH2
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;
Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;
nは3〜5であり;
前記第1の両親媒性カチオン性β−ヘアピンペプチドのC末端はカルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含み;
前記第1の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+7〜+10の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYから個別に選択され;
Zはそれぞれ、任意のアミノ酸から個別に選択され;
nは3〜5であり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+3〜+8の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなる、ペプチドヒドロゲル。 - ペプチドヒドロゲルであって、
前記ペプチドヒドロゲル内に封入されたナノ粒子を含み、前記ナノ粒子が、アンフォールドされ、β−ヘアピンコンフォメーションにない第1の両親媒性カチオン性β−ヘアピンペプチドと複合体化した核酸分子を含み、
前記ペプチドヒドロゲルが、β−ヘアピンコンフォメーションにある第2の両親媒性カチオン性β−ヘアピンペプチドの線維ネットワークから形成される、ペプチドヒドロゲル。 - 前記第1の両親媒性カチオン性β−ヘアピンペプチドが、VKVKVKVKVDPPTKVKVKVKV−NH2として記載されるアミノ酸配列を含むか、またはそれからなり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドが、VLTKVKTKVDPPTKVEVKVLV−NH2として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2に記載のペプチドヒドロゲル。 - 前記第1および第2の両親媒性カチオン性β−ヘアピンペプチドが長さ50アミノ酸以下である、請求項2または3に記載のペプチドヒドロゲル。
- 前記第1の両親媒性カチオン性β−ヘアピンペプチドの正味の静電荷が、中性pHで前記第2の両親媒性カチオン性β−ヘアピンペプチドの正味の静電荷と等しいか、またはそれより多くの正電荷を有する、請求項2から4のいずれか一項に記載のペプチドヒドロゲル。
- 中性pHで、前記第1の両親媒性カチオン性β−ヘアピンペプチドの前記正味の静電荷が+7〜+10であり、前記第2の両親媒性カチオン性β−ヘアピンペプチドの前記正味の静電荷が+3〜+8である、請求項5に記載のペプチドヒドロゲル。
- 中性pHで、前記第1の両親媒性カチオン性β−ヘアピンペプチドの前記正味の静電荷が+9であり、前記第2の両親媒性カチオン性β−ヘアピンペプチドの前記正味の静電荷が+5である、請求項6に記載のペプチドヒドロゲル。
- 前記第1の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n−NH2
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;
Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;
nは3〜5であり;
前記第1の両親媒性カチオン性β−ヘアピンペプチドのC末端はカルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含み;
前記第1の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+7〜+10の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から7のいずれか一項に記載のペプチドヒドロゲル。 - 前記第1の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n XDPPX(ZX)n;
(XZ)n XDPGX(ZX)n;または
(XZ)n X NGX(ZX)n(配列番号1)
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;
Zはそれぞれ、H、K、オルニチン、およびRのいずれか1つから個別に選択され;
nは3〜5であり;
前記第1の両親媒性カチオン性β−ヘアピンペプチドのC末端はカルボキシレートではなく、中性電荷または正電荷を有するペプチド改変を含み;
前記第1の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+7〜+10の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から8のいずれか一項に記載のペプチドヒドロゲル。 - 前記第1の両親媒性カチオン性β−ヘアピンペプチドが、VKVKVKVKVDPPTKVKVKVKV−NH2として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から9のいずれか一項に記載のペプチドヒドロゲル。
- 前記第2の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n X−[DPP、DPG、またはNG]−X(ZX)n
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYのいずれか1つから個別に選択され;
Zはそれぞれ、任意のアミノ酸から個別に選択され;
nは3〜5であり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+3〜+8の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から10のいずれか一項に記載のペプチドヒドロゲル。 - 前記第2の両親媒性カチオン性β−ヘアピンペプチドが、
(XZ)n XDPPX(ZX)n;
(XZ)n XDPGX(ZX)n;または
(XZ)n X NGX(ZX)n(配列番号94)
(式中、
Xはそれぞれ、F、I、L、M、T、V、W、およびYから個別に選択され;
Zはそれぞれ、任意のアミノ酸から個別に選択され;
nは3〜5であり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドは、中性pHで+3〜+8の正味の形式電荷を有する)
として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から11のいずれか一項に記載のペプチドヒドロゲル。 - 前記第2の両親媒性カチオン性β−ヘアピンペプチドが、VLTKVKTKVDPPTKVEVKVLV−NH2として記載されるアミノ酸配列を含むか、またはそれからなる、請求項2から12のいずれか一項に記載のペプチドヒドロゲル。
- 前記核酸分子がアンチセンス核酸分子である、請求項2から13のいずれか一項に記載のペプチドヒドロゲル。
- 剪断応力の印加の際に剪断減粘を受け、前記剪断応力の除去の際に流動学的回復を受ける、請求項2から14のいずれか一項に記載のペプチドヒドロゲル。
- 前記第1および/または第2の両親媒性カチオン性β−ヘアピンペプチドのN末端がアセチル化されている、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 前記第1および/または第2の両親媒性カチオン性β−ヘアピンペプチドのC末端がアミド化されている、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 前記核酸分子がマイクロRNAまたはそのミミックおよび/もしくはミメティックである、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 前記核酸分子が、
hsa−miR−1、hsa−miR−7、hsa−miR−10a、hsa−miR−15、hsa−miR−16、hsa−miR−23a−3p、hsa−miR−24−1、hsa−miR−24−2−5p、hsa−miR−26a、hsa−miR−26b、hsa−miR−27a−5p、hsa−miR−27b−5p、hsa−miR−27b−3p、hsa−miR−29a、hsa−miR−29b、hsa−miR−29c、hsa−miR−30b−5p、hsa−miR−30c−1、hsa−miR−33a、hsa−miR−34a、hsa−miR−95、hsa−miR−96、hsa−miR−100、hsa−miR−125a、hsa−miR−127、hsa−miR−130a、hsa−miR−130b、hsa−miR−132−3p、hsa−miR−133b、hsa−miR−134、hsa−miR−135a−1、hsa−miR−136、hsa−miR−139、hsa−miR−143、hsa−miR−145、hsa−miR−148a、hsa−miR−149、hsa−miR−181c、hsa−miR−181d、hsa−miR−182、hsa−mir−183、hsa−miR−190、hsa−miR−190b、hsa−miR−192、hsa−miR−195、hsa−miR−194、hsa−miR−200、hsa−miR−206、hsa−miR−212、hsa−miR−215、hsa−miR−221、hsa−miR−222−3p、hsa−miR−320d−1、hsa−miR−342、hsa−miR−370、hsa−miR−375、hsa−miR−376a−1、hsa−miR−376b、hsa−miR−491、hsa−miR−497、hsa−miR−502、hsa−miR−506、hsa−miR−509−1、hsa−miR−548、hsa−miR−643、hsa−miR−653、hsa−miR−664、hsa−miR−668、hsa−miR−676、hsa−miR−939、hsa−miR−1245、hsa−miR−1287、hsa−miR−1293、hsa−miR−1294、hsa−miR−1538、hsa−miR−2114、hsa−miR−3145、hsa−miR−3610、hsa−miR−3677、hsa−let−7c−5p、hsa−miR−590−3p、hsa−miR−4472−1、hsa−miR−8078、hsa−miR−4675、hsa−mir−155、hsa−mir−196b、hsa−mir−4524a、もしくはhsa−mir−4524bのいずれか1つ;または
そのミミックおよび/もしくはミメティックである、請求項18に記載のペプチドヒドロゲル。 - 前記ペプチドヒドロゲル内に分散された異種抗がん剤をさらに含む、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 前記異種抗がん剤が化学療法剤である、請求項20に記載のペプチドヒドロゲル。
- 剪断の非存在下で40パスカルより大きい貯蔵弾性率を含む、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 約10mM〜約400mMのNaClおよび約7.0〜約9.0のpHを含む、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 約150mMのNaClおよび約7.4のpHを含む、請求項23に記載のペプチドヒドロゲル。
- 約0.25%〜約4.0%w/vの前記第2の両親媒性カチオン性β−ヘアピンペプチドを含む、前記請求項のいずれか一項に記載のペプチドヒドロゲル。
- 約0.5%〜約2.0%w/vの第2の両親媒性カチオン性β−ヘアピンペプチドを含む、請求項25に記載のペプチドヒドロゲル。
- ペプチドヒドロゲルであって、
前記ペプチドヒドロゲル内に封入されたナノ粒子を含み、前記ナノ粒子が、アンフォールドされ、β−ヘアピンコンフォメーションにない第1の両親媒性カチオン性β−ヘアピンペプチドと複合体化したアンチセンス核酸分子を含み、
前記ペプチドヒドロゲルが、β−ヘアピンコンフォメーションに折り畳まれた第2の両親媒性カチオン性β−ヘアピンペプチドの線維ネットワークから形成され;
前記ペプチドヒドロゲルが、剪断応力の印加の際に剪断減粘を受け、前記剪断応力の除去の際に流動学的回復を受け;
前記第1の両親媒性カチオン性β−ヘアピンペプチドが、VKVKVKVKVDPPTKVKVKVKV−NH2として記載されるアミノ酸配列からなり;
前記第2の両親媒性カチオン性β−ヘアピンペプチドが、VLTKVKTKVDPPTKVEVKVLV−NH2として記載されるアミノ酸配列からなる、ペプチドヒドロゲル。 - 前記請求項のいずれか一項に記載のペプチドヒドロゲルを含有するシリンジ。
- 核酸分子を対象に投与する方法であって、請求項1から27のいずれか一項に記載のペプチドヒドロゲルを、前記対象中の標的位置に投与することを含む、方法。
- 前記ペプチドヒドロゲルを前記対象に投与することが、前記ペプチドヒドロゲルの前記対象中の前記標的位置への注射または噴霧送達を含む、請求項29に記載の方法。
- 対象におけるがんを処置または阻害する方法であって、
有効量の請求項1から27のいずれか一項に記載のペプチドヒドロゲルを、前記がんが存在するか、または存在するリスクがある前記対象中の標的位置に投与すること
を含み、
前記核酸分子が前記がんを阻害する、方法。 - 前記核酸分子が、前記がんを阻害するマイクロRNA、またはそのミミックおよび/もしくはミメティックである、請求項31に記載の方法。
- 前記標的位置が、前記がんが存在するか、または存在するリスクがある前記対象中の中皮細胞によって覆われている漿膜表面である、請求項31または請求項32に記載の方法。
- 前記漿膜表面が前記対象における漿膜体腔の一部である、請求項33に記載の方法。
- 前記漿膜体腔が、胸膜腔、心膜腔、前縦隔腔、後縦隔腔、腹膜腔、または精巣鞘膜腔である、請求項34に記載の方法。
- 前記がんが漿膜新生物である、請求項31から35のいずれか一項に記載の方法。
- 前記漿膜新生物が、胸膜中皮腫、腹膜中皮腫、胸腺上皮がん、卵巣癌、子宮頸がん、小細胞肺癌、非小細胞肺癌、卵巣癌、虫垂がん、またはグリオーマのいずれか1つである、請求項36に記載の方法。
- 前記漿膜新生物が、前記対象中の漿膜表面に転移した原発腫瘍の転移性成長を含む、請求項36に記載の方法。
- 前記ペプチドヒドロゲルを前記対象に投与することが、前記がんが存在するか、または存在するリスクがある前記対象中の前記漿膜表面の全部または一部を被覆するための、前記ペプチドヒドロゲルの注射または噴霧送達を含む、請求項31から38のいずれか一項に記載の方法。
- 前記がんが悪性胸膜中皮腫であり;
前記ペプチドヒドロゲルを前記対象に投与することが、前記胸膜中皮腫が存在するか、または存在するリスクがある前記対象における胸膜腔中の胸膜表面を被覆するための前記ペプチドヒドロゲルの注射または噴霧送達を含み;
前記マイクロRNAが、hsa−miR−1、hsa−miR−7、hsa−miR−10a、hsa−miR−15、hsa−miR−16、hsa−miR−23a−3p、hsa−miR−24−1、hsa−miR−24−2−5p、hsa−miR−26a、hsa−miR−26b、hsa−miR−27a−5p、hsa−miR−27b−5p、hsa−miR−27b−3p、hsa−miR−29a、hsa−miR−29b、hsa−miR−29c、hsa−miR−30b−5p、hsa−miR−30c−1、hsa−miR−33a、hsa−miR−34a、hsa−miR−95、hsa−miR−96、hsa−miR−100、hsa−miR−125a、hsa−miR−127、hsa−miR−130a、hsa−miR−130b、hsa−miR−132−3p、hsa−miR−133b、hsa−miR−134、hsa−miR−135a−1、hsa−miR−136、hsa−miR−139、hsa−miR−143、hsa−miR−145、hsa−miR−148a、hsa−miR−149、hsa−miR−181c、hsa−miR−181d、hsa−miR−182、hsa−mir−183、hsa−miR−190、hsa−miR−190b、hsa−miR−192、hsa−miR−195、hsa−miR−194、hsa−miR−200、hsa−miR−206、hsa−miR−212、hsa−miR−215、hsa−miR−221、hsa−miR−222−3p、hsa−miR−320d−1、hsa−miR−342、hsa−miR−370、hsa−miR−375、hsa−miR−376a−1、hsa−miR−376b、hsa−miR−491、hsa−miR−497、hsa−miR−502、hsa−miR−506、hsa−miR−509−1、hsa−miR−548、hsa−miR−643、hsa−miR−653、hsa−miR−664、hsa−miR−668、hsa−miR−676、hsa−miR−939、hsa−miR−1245、hsa−miR−1287、hsa−miR−1293、hsa−miR−1294、hsa−miR−1538、hsa−miR−2114、hsa−miR−3145、hsa−miR−3610、およびhsa−miR−3677のうちの1つまたは複数である、請求項31から39のいずれか一項に記載の方法。 - 前記ペプチドヒドロゲル内に封入された異種抗がん剤を前記対象に投与することをさらに含む、請求項31から40のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862628961P | 2018-02-10 | 2018-02-10 | |
US62/628,961 | 2018-02-10 | ||
PCT/US2019/017354 WO2019157381A1 (en) | 2018-02-10 | 2019-02-08 | Nanoparticle-hydrogel composite for nucleic acid molecule delivery |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021512892A true JP2021512892A (ja) | 2021-05-20 |
JPWO2019157381A5 JPWO2019157381A5 (ja) | 2022-02-16 |
JP7424984B2 JP7424984B2 (ja) | 2024-01-30 |
Family
ID=65529809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020542544A Active JP7424984B2 (ja) | 2018-02-10 | 2019-02-08 | 核酸分子送達のためのナノ粒子-ヒドロゲル複合材料 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11904057B2 (ja) |
EP (1) | EP3749288A1 (ja) |
JP (1) | JP7424984B2 (ja) |
CN (1) | CN111787912A (ja) |
AU (1) | AU2019216781A1 (ja) |
CA (1) | CA3089396A1 (ja) |
WO (1) | WO2019157381A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
CN114908123B (zh) * | 2021-02-08 | 2024-02-02 | 中国科学院生物物理研究所 | 介导非编码小rna进入细胞的方法 |
CN112941185B (zh) * | 2021-03-26 | 2023-06-23 | 杭州医学院 | miR-29a作为标志物在制备恶性间皮瘤检测试剂盒中的应用 |
CN113181421B (zh) * | 2021-05-12 | 2022-11-15 | 广州贝奥吉因生物科技股份有限公司 | 一种具有抗菌和免疫调节功能的水凝胶伤口敷料及制备方法 |
CN114533953B (zh) * | 2022-01-24 | 2022-12-16 | 华南理工大学 | 一种纳米颗粒复合水凝胶神经导管及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523118A (ja) * | 2005-11-14 | 2009-06-18 | ユニバーシティー、オブ、デラウェア | 新規ハイドロゲルおよびそれらの使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4584986B2 (ja) | 2004-04-27 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | 2−アリールプロピル部分を含む1本鎖及び2本鎖オリゴヌクレオチド |
US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
JP2008504840A (ja) | 2004-06-30 | 2008-02-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 非リン酸骨格結合を含むオリゴヌクレオチド |
EP1828215A2 (en) | 2004-07-21 | 2007-09-05 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
WO2008088858A2 (en) | 2007-01-17 | 2008-07-24 | The Johns Hopkins University | Compositions and methods featuring micronas for treating neoplasia |
US8834926B2 (en) | 2008-08-08 | 2014-09-16 | University Of Delaware | Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels |
US10086108B2 (en) | 2015-01-22 | 2018-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrogels and use thereof in anastomosis procedures |
-
2019
- 2019-02-08 US US16/967,302 patent/US11904057B2/en active Active
- 2019-02-08 JP JP2020542544A patent/JP7424984B2/ja active Active
- 2019-02-08 EP EP19707555.9A patent/EP3749288A1/en active Pending
- 2019-02-08 WO PCT/US2019/017354 patent/WO2019157381A1/en unknown
- 2019-02-08 AU AU2019216781A patent/AU2019216781A1/en active Pending
- 2019-02-08 CN CN201980012620.8A patent/CN111787912A/zh active Pending
- 2019-02-08 CA CA3089396A patent/CA3089396A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523118A (ja) * | 2005-11-14 | 2009-06-18 | ユニバーシティー、オブ、デラウェア | 新規ハイドロゲルおよびそれらの使用 |
Non-Patent Citations (1)
Title |
---|
HABIBI, N. ET AL: "Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery", NANO TODAY, vol. 11, JPN6023006670, 2016, pages 41 - 60, XP029492215, ISSN: 0004992140, DOI: 10.1016/j.nantod.2016.02.004 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019157381A1 (en) | 2019-08-15 |
EP3749288A1 (en) | 2020-12-16 |
AU2019216781A1 (en) | 2020-08-20 |
CN111787912A (zh) | 2020-10-16 |
CA3089396A1 (en) | 2019-08-15 |
JP7424984B2 (ja) | 2024-01-30 |
US11904057B2 (en) | 2024-02-20 |
US20200360296A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7424984B2 (ja) | 核酸分子送達のためのナノ粒子-ヒドロゲル複合材料 | |
Suh et al. | Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation | |
CN109804070B (zh) | 具有改进的细胞渗透性的肽核酸复合物和包含其的药物组合物 | |
Ding et al. | A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer | |
JP6527516B2 (ja) | リポソーム粒子、前述のものを作製する方法及びその使用 | |
CA2917320C (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease | |
JP2018100284A (ja) | 線維症および炎症状態を処置するための多標的調整 | |
CN112135907A (zh) | 具有内含体逃逸能力的肽核酸复合物及其用途 | |
Wan et al. | Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells | |
EP3107549B1 (en) | Anionic polyplexes for use in the delivery of nucleic acids | |
Avitabile et al. | Incorporation of naked peptide nucleic acids into liposomes leads to fast and efficient delivery | |
US20240026357A1 (en) | Modified mir-135, conjugated form thereof, and uses of same | |
Kim et al. | PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs | |
JP6560190B2 (ja) | 抗腫瘍作用を有する新規rna配列 | |
US11149275B2 (en) | Device and method to treat esophageal disorders | |
US11618901B2 (en) | Anti-miRNA carrier conjugated with a peptide binding to a cancer cell surface protein and use thereof | |
WO2022040168A2 (en) | Anti-seed pnas and microrna inhibition | |
US20220087947A1 (en) | Nanoparticle for delivering ribonucleoprotein and use thereof | |
WO2023212503A1 (en) | Synthetic triplex peptide nucleic acid-based inhibitors for cancer therapy | |
KR101814879B1 (ko) | 유전자 전달체 및 그 제조방법 | |
Duo et al. | Syk Receptor | |
CN117337330A (zh) | TMEM173 saRNA组合物和使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231010 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7424984 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |